ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Keller et al have previously shown that telomere length measured in peripheral blood of patients with CML correlates with disease stage, clinical prognostic scores, and response to treatment.26 Also, Samassekou et al reported that in the early stage of CML ontogenesis, long telomeres on key chromosomes may contribute to a cell proliferation advantage.27 In another study, Braig et al demonstrated that telomerase-targeting strategy could alleviate the tumor promoting effect of BCR-ABL via induce senescence in CML-like cells.28